» Articles » PMID: 12394688

Management of Post-chemotherapy Residual Masses in Advanced Seminoma

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2002 Oct 24
PMID 12394688
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases.

Materials And Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients.

Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes.

Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.

Citing Articles

Contemporary surgical management of testicular seminoma.

Passarelli R, Pfail J, Jang T Transl Cancer Res. 2024; 13(11):6463-6472.

PMID: 39697723 PMC: 11651731. DOI: 10.21037/tcr-24-241.


MicroRNA-371a-3p-The Novel Serum Biomarker in Testicular Germ Cell Tumors.

Nestler T, Schoch J, Belge G, Dieckmann K Cancers (Basel). 2023; 15(15).

PMID: 37568759 PMC: 10417034. DOI: 10.3390/cancers15153944.


End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention?.

Joel A, Singh A, Hepzibah J, Devasia A, Kumar S, Gnanamuthu B South Asian J Cancer. 2023; 11(4):315-321.

PMID: 36756102 PMC: 9902077. DOI: 10.1055/s-0041-1735480.


Characteristics of lung metastasis in testicular cancer: A large-scale population analysis based on propensity score matching.

Guo A, Gu J, Yang J Front Surg. 2022; 9:959573.

PMID: 36406361 PMC: 9672078. DOI: 10.3389/fsurg.2022.959573.


Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma.

Dieckmann K, Klemke M, Grobelny F, Radtke A, Dralle-Filiz I, Wulfing C Front Oncol. 2022; 12:889624.

PMID: 35600346 PMC: 9121896. DOI: 10.3389/fonc.2022.889624.